The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-01

Study Completion Date

2021-11-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the safety and effectiveness of EVARREST™ Sealant Matrix (EVARREST™ Fibrin Sealant Patch) (EVARREST™) in controlling mild or moderate soft tissue \& parenchymal bleeding during open hepatic, abdominal, pelvic, retroperitoneal, and thoracic (non-cardiac) surgery in paediatric patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Paediatric EVICEL® Soft Tissue and Parenchymal Organ Bleeding Study

NCT02227706

Hemorrhage Soft Tissue Bleeding

COMPLETED PHASE3

The SURGICEL® Powder Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding (China Study)

NCT03783039

Hemorrhage

COMPLETED NA

A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft Tissue

NCT01719172

Non-emergent, Soft Tissue Procedures, Performed Via an Open Approach

COMPLETED NA

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries

NCT01754480

Parenchymous Tissue Surgical Bleeding

COMPLETED PHASE3

A Study of Fibrocaps in Liver Surgery in the Netherlands

NCT01256190

Postoperative Hemorrhage

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open label, prospective, randomised, multicentre, controlled, clinical study comparing EVARREST to SURGICEL (oxidized regenerated cellulose (ORC)) (Control) as an adjunct to haemostasis when conventional methods of controlling mild or moderate bleeding are ineffective or impractical during surgery in paediatric patients.

At least 40 qualified paediatric subjects with an appropriate mild or moderate bleeding Target Bleeding Site (TBS) will be randomised in a 1:1 allocation ratio to either EVARREST or SURGICEL (control). Absolute time to haemostasis will be assessed as well as haemostasis at 4 and 10 minutes from randomisation.

Enrolment will be staggered by age (as required by the European Medicines Agency (EMA) Paediatric Committee). The first 36 subjects enrolled will be aged ≥1 years to \<18 years of age. Enrolment of a subsequent group will include 4 subjects from 1 month (≥ 28 days from birth) to \<1 year of age will follow. Ongoing safety assessment will ensure adequate safety monitoring occur during the staged enrolment.

Subjects will be followed post-operatively through hospital discharge and at 30 days (+/-14 days) post-surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemorrhage Soft Tissue Bleeding Hepatic Parenchyma Bleeding

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EVARREST™ Sealant Matrix

EVARREST™ Sealant Matrix/Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).

Group Type EXPERIMENTAL

EVARREST™ Sealant Matrix

Intervention Type BIOLOGICAL

EVARREST® Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.

SURGICEL® Absorbable Hemostat

SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.

Group Type ACTIVE_COMPARATOR

SURGICEL®

Intervention Type DEVICE

SURGICEL® Absorbable Hemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EVARREST™ Sealant Matrix

EVARREST® Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.

Intervention Type BIOLOGICAL

SURGICEL®

SURGICEL® Absorbable Hemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

EVARREST™ Fibrin Sealant Patch oxidized regenerated cellulose

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Paediatric subjects aged ≥28 days (≥ 1 month) to \<18 years, requiring non-emergent open hepatic, abdominal, retroperitoneal, pelvic or thoracic (non-cardiac) surgical procedures. i) The first 36 subjects to be enrolled will be subjects aged ≥1 years to \<18 years. ii) The next 4 subjects to be enrolled will be subjects aged ≥28 days to \<1 year.
* The subject's parent/legal guardian must be willing to give permission for the subject to participate in the trial, and provide written informed consent for the subject. In addition, assent must be obtained from paediatric subjects who possess the intellectual and emotional ability to comprehend the concepts involved in the trial. If the paediatric subject is not able to provide assent (due to age, maturity and/or inability to intellectually and/or emotionally comprehend the trial), the parent/legal guardian's written Informed Consent for the subject will be acceptable for the subject to be included in the study.
* Presence of an appropriate mild or moderate bleeding soft tissue or hepatic parenchyma Target Bleeding Site (TBS) identified intra-operatively by the surgeon;
* Ability to firmly press trial treatment at TBS until 4 minutes after randomisation

Exclusion Criteria

* Subjects with known intolerance to blood products or to one of the components of the study product or is unwilling to receive blood products;
* Female subjects, who are of childbearing age (i.e. adolescent), who are pregnant or nursing;
* Subject is currently participating or plans to participate in any other investigational device or drug without prior approval from the Sponsor;
* Subjects who are known, current alcohol and/or drug abusers
* Subjects admitted for trauma surgery
* Subjects with any pre or intra-operative findings identified by the surgeon that may preclude conduct of the study procedure.
* Subject with TBS in an actively infected field (Class III Contaminated or Class IV Dirty or Infected)
* TBS is from large defects in arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of the EVARREST™ or SURGICEL® to blood flow and pressure during healing and absorption of the product;
* TBS with major arterial bleeding requiring suture or mechanical ligation;
* Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine.

Minimum Eligible Age

28 Days

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No